Covaxin 77.8% Effective Against Covid, 65.2% Works on Delta: Bharat Biotech in Final Phase 3 Trial Analysis

July 3, 2021

Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India.

Previous articleCovaxin phase 3 trial data released: Jab shows 65.2% efficacy against Delta COVID-19 variant, says company

Next articleLanguage Barrier: Gurugram Police Take Over A Year to File Case

Covaxin 77.8% Effective Against Covid, 65.2% Works on Delta: Bharat Biotech in Final Phase 3 Trial Analysis

Similar Articles

Most Popular

Covaxin 77.8% Effective Against Covid, 65.2% Works on Delta: Bharat Biotech in Final Phase 3 Trial Analysis

Similar Articles

Lakhimpur Kheri: Viral Video Shows Farmers Being Run Over by SUV, Oppn Questions Union Minister’s Claims

Karnataka: 3 Dead After Drinking Contaminated Water, 108 Show Similar Symptoms

Most Popular

AMPC reforms: BJP digs out Siddaramaiah’s old letter

India UAE Grow Bilateral Trade Amidst Worldwide Geopolitical Shifts

Author Amish on why Bollywood doesn’t adapt ancient Sanskritic texts into films